a Objective: To assess the performance of an adapted American Diabetes Association (ADA) risk score and the concise Finnish Diabetes Risk Score (FINRISC) for predicting type 2 diabetes development in women with and at risk of HIV infection.
Introduction
Type 2 diabetes is a common comorbidity in people living with HIV (PLWH) in the United States, possibly fueling the increased risk of cardiovascular and renal disease and mortality this population is facing [1] [2] [3] . PLWH in the United States are two to four times more likely to develop diabetes than their HIV-negative counterparts [4, 5] , and have a national diabetes prevalence 4% higher than the general adult population [6] . The increased diabetes risk PLWH face has been linked to chronic inflammation, medication-induced dysglycemia, and immunosuppression [7] [8] [9] [10] [11] . Furthermore, traditional diabetes risk factors such as older age, minority race, and obesity have been found to have a stronger effect on diabetes risk among HIV-positive than HIV-negative persons [1] . There are 1.2 million PLWH in the United States [12] and those at increased diabetes risk should be identified and treated appropriately to potentially prevent diabetes and its complications.
To minimize the harms of inappropriate glucose testing (e.g. costs, anxiety), expert groups recommend a twostage diabetes risk screening approach -noninvasive risk assessment followed by glucose testing [13, 14] . This approach involves using noninvasive risk scores such as the American Diabetes Association (ADA) diabetes risk score [15] or the Finnish Diabetes Risk Score (FINRISC) [16] to identify those who should be offered diagnostic glucose testing. In the general population, the ADA and FINRISC scores have been found to be effective and practical tools for identifying people with dysglycemia in clinical practice [17] [18] [19] [20] [21] .
The ADA and FINRISC scores should be tested among PLWH to determine if they are effective diabetes risk screening tools in the setting of HIV infection. Although a recent cross-sectional study tested FINRISC among PLWH, the study did not include an HIV-negative sample for comparing tool performance [22] . Efforts have also been directed towards developing an HIV-specific diabetes risk equation [23] but a practical scoring system has not been developed. It remains unknown what risk score would most accurately identify PLWH at risk for diabetes. Thus, we aimed to assess and compare the performance of the ADA and FINRISC diabetes risk scores in a longitudinal cohort study of HIV-positive and HIV-negative women.
Methods

Study design and population
This was a longitudinal analysis of the Women's Interagency HIV Study (WIHS). WIHS is an ongoing multicentre prospective cohort study established in 1994 in the United States to investigate the progression of HIV in women with and at risk for HIV infection [24] . A total of 4982 women (3678 HIV-positive and 1304 HIV-negative) were enrolled in four waves: 1994-1995 (n ¼ 2623), 2001-2002 (n ¼ 1143), 2011-2013 (n ¼ 371), and 2013-2015 (n ¼ 845) from 11 cities (Atlanta, Birmingham, Bronx, Brooklyn, Chapel Hill, Chicago, Jackson, Los Angeles, Miami, San Francisco, and Washington DC). Every 6 months, WIHS participants complete a comprehensive physical examination, provide biological specimens for blood testing, and complete an intervieweradministered questionnaire, which collects information on demographics, disease characteristics, and specific antiretroviral therapy (ART) use. The WIHS study protocol and consent forms have been approved by the Institutional Review Board at each study site, and all participants have provided written informed consent.
Hemoglobin A1c (A1c) and fasting blood glucose (FBG) testing were first introduced in WIHS in October 2000. At each semiannual visit, participants are asked if they use any antidiabetic medication and if they had been told they have diabetes. The index visit was defined as the first visit at which FBG, A1c, self-reported antidiabetic medication use, and self-reported diabetes data were available. Participants with prevalent diabetes (defined as FBG ! 126 mg/dl or A1c ! 6.5% at the index visit; or self-reported antidiabetic medication use or self-reported diabetes before or at the index visit) were excluded. To be included in our analysis, participants had to have data on FBG, A1c, self-reported antidiabetic medication use, and self-reported diabetes at least once annually for 3 years after the index visit.
Exposures and outcome
Race, age, BMI, and self-reported health insurance status were compared between HIV-positive and HIV-negative women at the index visit. Prediabetes prevalence, defined as either FBG of 100-125 mg/dl or A1c of 5.7-6.4%, was also compared at the index visit. In HIV-positive women, we calculated the prevalence of stavudine use, ritonavir use or any protease inhibitor use as of the index visit since these HIV medications have been linked to increased diabetes risk [4, 10] . Undetectable HIV RNA was defined as HIV-1 RNA less than 80 copies/ml at index visit. [16] . We used the FINRISC concise model, which excludes physical activity and fruit and vegetable consumption [16] .
The outcome of interest was incident diabetes, defined as the first time within 3 years after the index visit at which the participant reported antidiabetic medication use (confirmed with A1c ! 6.5% or FBG ! 126 mg/dl), FBG ! 126 mg/dl (confirmed with a report of antidiabetic medication use or a second FBG measure !126 mg/ dl or A1c ! 6.5%), or self-report of diabetes (confirmed with a report of antidiabetic medication use or two FBG measures !126 mg/dl or concurrent A1c ! 6.5% and FBG ! 126 mg/dl) [5] .
Statistical analysis
Wilcoxon rank-sum tests were used to test for differences between HIV-positive and HIV-negative women in demographic and clinical characteristics at the index visit. Pearson chi-square tests were used to test for associations between categorical characteristics and HIV status at the index visit.
For each woman, we calculated an ADA and a FINRISC score at index visit and determined whether diabetes developed within 3 years following the index visit. To categorize women as being at low or high diabetes risk, we chose risk score thresholds (low risk, high risk) that gave equal weight to sensitivity and specificity. We compared the sensitivity, specificity, positive predictive value and negative predictive value of the models between HIV-positive and HIV-negative women using score thresholds selected for this study with two-sample tests of proportions.
We calculated the area under the receiver operating characteristics curves (AUROC) for HIV-positive and HIV-negative women to assess the ability of the models to discriminate those with and without diabetes; values of at least 0.8 were considered indicative of good model discrimination [26] . Ninety-five percent confidence intervals (95% CI) were calculated to quantify the precision in the estimated sensitivity, specificity, positive predictive value, negative predictive value, and AUROC for HIV-positive and HIV-negative women. Significant differences in receiver operating characteristics (ROC) curves between HIV-positive and HIV-negative women (e.g. ROC1 and ROC2) were determined as follows:
We compared diabetes risk classification (via sensitivity, specificity, positive predictive value, negative predictive value, and AUROC) for ADA and FINRISC scores in HIV-positive women at different calendar periods. These were selected based on the years corresponding to early highly active ART (HAART) era ( included, while HIV-negative women excluded were more likely to be African American than those included (see Table, Supplemental Digital Content 2, http:// links.lww.com/QAD/B361, which presents demographic data of excluded women by HIV status).
Participant median age was 40 years and 61% were African-American. As shown in Table 1 , HIV-positive women were on average 3 years older than HIV-negative women (41 vs. 38 years, P < 0.001). The prevalence of prediabetes was lower in HIV-positive than in HIVnegative women (25 vs. 33%, P ¼ 0.003). More HIVpositive than HIV-negative women reported having health insurance (92 vs. 66%, P < 0.001). Forty-three percent of the HIV-positive women had a history of stavudine use, 24% had a history of ritonavir use, 41% were virally suppressed, and 50% had a median CD4 þ cell count between 300 and 653 cells/ml ( Table 1 ).
The risk factor prevalence and score distribution for ADA and FINRISC by HIV status are reported in Table 2 . The median ADA risk score was 3 for both HIV-positive and negative women, and the median FINRISC score was 6 for both groups. In both models, obesity was the most prevalent risk factor, present in 53% of HIV-positive and 54% of HIV-negative women according to ADA (based on BMI and waist circumference) and in 35% of HIVpositive and 43% of HIV-negative women according to FINRISC (based on BMI). According to ADA, history of hypertension was also common, present in 46% of HIVpositive and 41% of HIV-negative women; this was followed by family history of diabetes, present in nearly 30% of both women groups. Three years after the index visit, 69 (6%) HIV-positive and 21 (5%) HIV-negative women developed diabetes.
To evaluate ADA model performance, the sensitivity and specificity of all possible risk score cutoffs were explored by HIV status (see Table, Supplemental Digital Content 3A, http://links.lww.com/QAD/B361, which presents sensitivity and specificity values for all ADA score cutoffs). The score cutoff ADA uses to indicate high diabetes risk (!5) had a poor sensitivity (28%) in both HIV-positive and HIVnegative women. A score of at least 3 was deemed the best performing for identifying high-risk HIV-positive (sensitivity ¼ 77%, specificity ¼ 42%) and HIV-negative (sensitivity ¼ 81%, specificity ¼ 49%) women in this study (see ROC curves in Fig. 1 ). Using this cutoff, the ADA model classified 60% of HIV-positive and 52% of HIVnegative women as having high diabetes risk (Table 3) The sensitivity and specificity of all possible FINRISC score cutoffs were also explored by HIV status (see Table, Supplemental Digital Content 3B, http://links.lww.-com/QAD/B361, which presents sensitivity and specificity values for all FINRISC score cutoffs). The score cutoff FINRISC uses to indicate high diabetes risk (!9) had a suboptimal sensitivity in HIV-positive (42%) and HIV-negative women (62%). A score of at least 6 was deemed the best performing for identifying high-risk HIV-positive (sensitivity ¼ 72%, specificity ¼ 49%) and HIV-negative (sensitivity ¼ 86%, specificity ¼ 52%) women in this study (see ROC curves in Fig. 1 ). Using this cutoff, the FINRISC model classified 52% of HIVpositive and 50% of HIV-negative women as having high diabetes risk (Table 3) Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Discussion
Early identification of PLWH at risk for diabetes can facilitate prompt initiation of preventive measures to forestall the development of diabetes and its complications. To inform such efforts, we assessed the performance of the concise FINRISC model and an adapted ADA model in a predominantly minority population of HIV-positive and HIV-negative women. Our assessment showed that performances of the concise FINRISC and adapted ADA models were broadly similar among HIV-positive and HIVnegative women. However, model performance was suboptimal in both groups, while greater misclassification was generally observed among HIV-positive women.
Exploring the contribution of HIV-specific risk factors in these models could unmask performance differences and could improve risk classification in HIV-positive women.
At baseline, HIV-positive women had a lower prediabetes prevalence than HIV-negative women (25 vs. 33%); yet, a similar proportion of HIV-positive and negative women developed diabetes within 3 years (6 and 5%, respectively). This may be an early signal that PLWH could be moving from prediabetes to diabetes faster than HIVnegative populations. We also observed an annual diabetes incidence of $2%, which is higher than the $1% annual incidence observed in the United States general population [27] . This is likely because over half of WIHS women have overweight or obesity compared with the 38% obesity prevalence reported in the general population [28] . Overall, HIV-positive women have a high prevalence of diabetes risk factors and may develop the disease faster than HIV-negative women.
The sensitivity (77-81%) and specificity (42-49%) of the adapted ADA model observed in this study differ from the sensitivity (89-98%) and specificity (4-40%) observed in the United States general population [17] . Differences in populations, risk score cutoffs, and in risk factors included in the models (e.g. physical activity, race and Diabetes risk prediction in HIVR and HIVS women Galaviz et al. 2771 Table 2 . Risk factor prevalence, risk scores, and diabetes incidence by HIV status. dyslipidaemia) may explain these differences. The sensitivity (72-86%) and specificity (49-52%) of the concise FINRISC model observed in this study were similar to the sensitivity (79%) and specificity (49%) observed in the United States general population [18] . Regarding FINRISC performance in HIV-positive populations, the model has been found to be more specific (90%) and sensitive (65%) among HIV-positive Values obtained using a score cutoff of at least 3 for both HIV-positive and HIV-negative participants.
Risk factors included in models
b
Values obtained using a score cutoff of at least 6 for both HIV-positive and HIV-negative participants.
c Low-risk participants were those achieving a score of less than 3 for ADA and less than 6 for FINRISC. High-risk participants were those achieving a score of at least 3 for ADA and at least 6 for FINRISC.
individuals from London [22] than among WIHS women in this study. In addition to population characteristics, these differences could be related to the different score cutoffs we used to improve model discrimination and the different observation periods and models tested (i.e. FINRISC concise vs. full).
The performance of the adapted ADA and the concise FINRISC models did not significantly differ between HIV-positive and HIV-negative women. However, a greater percentage of HIV-positive than negative women were misclassified as having (lower specificity) or not having diabetes (lower sensitivity). It is possible that misclassification occurred more often in HIV-positive women due to HIV-related factors that are not measured in these models. Indeed diabetes risk classification has been found to be better among HIV-positive individuals when HIV-specific risk factors are included [22] . Inclusion of HIV-specific risk factors such as CD4 þ cell count could potentially unmask differences in the performance of these tools and improve risk classification among HIV-positive women.
Identifying asymptomatic persons with dysglycemia through targeted screening in healthcare settings has been recommended by numerous organizations [14, 29, 30] . Though HIV clinical guidelines mirror these screening recommendations [31] , risk management in HIV-positive populations has fallen below the recommended standards [32] . This is compounded by the lack of HIV-specific risk screening tools [32] . Diabetes risk screening in HIV care can help estimate, communicate and monitor risk to motivate adherence to lifestyle change or therapies, and to allocate scarce prevention resources and strategies appropriately [32] . For this, a high performing, practical risk screening tool to conduct targeted glucose testing in HIV care is needed.
These findings should be interpreted in light of the study limitations. First, we did not include men in this analysis, which limits conclusions about the performance of these tools in HIV-positive populations to women only. Second, since physical activity and fruit and vegetable consumption data were not complete in WIHS, we excluded physical activity from the ADA model and used the concise FINRISC model. Third, this analysis focused on diabetes as the outcome and did not explore dysglycemia at-large (i.e. prediabetes and diabetes). Finally, we only explored diabetes risk over 3 years, which does not correspond with the time period FINRISC assesses (i.e. 10-year diabetes risk). The analysis may also be limited due to the small number of diabetes cases we could detect and to the lack of score validation over a shorter time interval.
Diabetes is an increasingly important comorbidity in PLWH. Diabetes risk screening in HIV care can help estimate, communicate and monitor risk to motivate adherence to lifestyle change or therapies, and to allocate scarce prevention resources and strategies appropriately. To inform such efforts, we assessed the performance of the concise FINRISC model and an adapted ADA model in a predominantly minority population of HIV-positive and HIV-negative women. Our assessment showed that the performance of the models was broadly similar between women with and at risk of HIV, though greater misclassification was generally observed among women with HIV. Inclusion of HIV-specific risk factors known to contribute to diabetes risk may improve identification of HIV-positive individuals at increased diabetes risk. Longterm studies in multiethnic, mixed-gender longitudinal cohorts in this area are needed. We refer to the first visit at which fasting blood glucose, hemoglobin A1c, self-reported antidiabetic medication use, and self-reported diabetes data were available as the index visit. Time frames were selected based on the years corresponding to early HAART era (2000) (2001) (2002) (2003) and late HAART era (2010-2013).
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